Candace Nguyen, MD
Family Medicine · Woodlyn, PANPI 1518300748
Payments from drug & device makers
Across 600 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- AstraZeneca$1K
- GSK$970
- Astellas Pharma US Inc$632
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,548100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $1,367 |
| Lilly USA, LLC | 74 | $1,287 |
| AbbVie(2 entities) | 76 | $1,282 |
| AstraZeneca | 63 | $1,155 |
| GSK | 59 | $970 |
| Astellas Pharma US Inc | 31 | $632 |
| Boehringer Ingelheim | 34 | $626 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $355 |
| Amarin Pharma, Inc. | 17 | $293 |
| Merck | 19 | $288 |
| Pfizer | 18 | $284 |
| Otsuka America Pharmaceutical, Inc. | 13 | $243 |
| Amgen | 14 | $236 |
| Bayer | 9 | $166 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $156 |
| Novartis | 11 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $135 |
| Abbott | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| Dexcom, Inc. | 3 | $77 |
| Biohaven Pharmaceuticals, Inc. | 4 | $75 |
| Radius Health, Inc. | 4 | $71 |
| Sanofi | 2 | $70 |
| Lundbeck LLC | 2 | $64 |
| Exact Sciences | 2 | $60 |
| Johnson & Johnson | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Kaleo, Inc. | 2 | $41 |
| Gilead | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$10,574 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $69,259 |
| EliquisApixaban | 46 | $45,914 |
| JardianceEmpagliflozin | 40 | $35,220 |
| XareltoRivaroxaban | 24 | $31,605 |
| JanuviaSitagliptin Phosphate | 21 | $25,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $23,204 |
| TrulicityDulaglutide | 13 | $22,031 |
| VascepaIcosapent Ethyl | 12 | $12,208 |
| Atorvastatin Calcium | 292 | $4,423 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,459 |
| Risedronate Sodium | 13 | $2,304 |
| Gabapentin | 110 | $2,011 |
| Rosuvastatin Calcium | 84 | $1,307 |
| Fluticasone Propionate | 81 | $1,295 |
| Lisinopril | 106 | $1,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,155 | $69,25966 claims |
| PfizerEliquis | $284 | $45,91446 claims |
| Boehringer IngelheimJardiance | $626 | $35,22040 claims |
| Johnson & JohnsonXarelto | $54 | $31,60524 claims |
| MerckJanuvia | $288 | $25,36221 claims |
| GSKTrelegy Ellipta | $970 | $23,20421 claims |
| Lilly USA, LLCTrulicity | $1,287 | $22,03113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Woodlyn
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.